Country: Canada
Language: English
Source: Health Canada
DIFLUNISAL
TEVA CANADA LIMITED
N02BA11
DIFLUNISAL
500MG
TABLET
DIFLUNISAL 500MG
ORAL
60/100/500
Prescription
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Active ingredient group (AIG) number: 0113161002; AHFS:
CANCELLED POST MARKET
2018-04-30
PRODUCT MONOGRAPH NOVO-DIFLUNISAL (diflunisal) Film-coated Tablets 250 and 500 mg THERAPEUTIC CLASSIFICATION Analgesic, Anti-Inflammatory Agent Teva Canada Limited Date of Preparation: 30 Novopharm Court June 19, 2014 Toronto ON M1B 2K9 Control # 174380 2 NAME OF DRUG Novo-DIFLUNISAL (diflunisal tablets, USP) 250 and 500 mg THERAPEUTIC CLASSIFICATION Anti-Inflammnatory, Analgesic Agent ACTION AND CLINICAL PHARMACOLOGY Diflunisal is a non-steroidal drug with analgesic, anti- inflammatory and antipyretic properties. The precise mechanism of the analgesic and anti-inflammatory actions of diflunisal is not known, however, it appears to be a peripherally-acting analgesic drug. Diflunisal is a prostaglandin synthetase inhibitor. In animals, prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain. Since prostaglandins are known to be among the mediators of pain and inflammation, the mode of action of diflunisal may be due in part to a decrease of prostaglandins in peripheral tissues. Pharmacokinetics and Metabolism Diflunisal is rapidly and completely absorbed following oral administration with peak plasma concentrations occurring between 2 to 3 hours. The drug is excreted in the urine as two soluble glucuronide conjugates accounting for about 90% of the administered dose. Little or no diflunisal is excreted in the feces. Diflunisal appears in human milk in concentrations of 2 - 7% of those in plasma. More than 99% of diflunisal in plasma is bound to proteins. As is the case with salicylic acid, concentration-dependent pharmacokinetics prevail when diflunisal is administered; a doubling of dosage produces a greater than doubling of drug accumulation. The effect becomes more apparent with repetitive doses. Following single doses, peak plasma concentrations of 41 ± 11 µg/mL (mean ± S.D.) were observed following 250 mg 3 doses 87 ± 17 µg/mL were observed following 500 mg and 124 ± 11 µg/mL following single 1000 mg doses. However, following administration of 250 mg b.i.d., a Read the complete document